The treatment being tested combines three medications: fosfomycin and metronidazole, which are antibiotics that fight bacterial infections, and molgramostim (also called Repomol), which is a substance that helps boost the body’s immune system. These medications will be given directly into the abdominal cavity during surgery. Some patients will receive these medications, while others will receive a placebo with sodium chloride solution.

During the study, doctors will collect fluid samples from the abdominal cavity and blood samples to measure how well the treatment is working. They will also monitor patients’ recovery after surgery. The treatment will be given as a single dose during the surgical procedure, and patients will be followed to evaluate their healing process.

The purpose of the study is to determine if this combination of medications can optimize the treatment of patients with multiquadrant peritonitis, which means the infection affects multiple areas of the abdomen. Participants in the study will receive either the medication combination or a placebo. The study will monitor changes in certain biological markers and overall recovery to assess the effectiveness of the treatment.

Throughout the study, participants will undergo regular assessments to track their progress and any changes in their condition. The trial aims to provide valuable insights into improving treatment strategies for those affected by this challenging condition. The study is expected to continue until 2030, with recruitment starting in 2025.

The purpose of the study is to evaluate whether this antibiotic wash can lower the chances of getting an abscess by at least 50%. Participants in the study will undergo the standard surgical procedure to remove the appendix, known as a laparoscopic appendectomy, and then receive the antibiotic wash. The study will monitor participants for 30 days after the surgery to check for any signs of an abscess. Additionally, other aspects such as wound infections, the need for further treatment, and overall recovery will be observed for up to 90 days.

This trial is designed to gather information on the effectiveness and safety of using antibiotics in this way. By participating, researchers hope to find a better way to prevent complications after surgery for those with complicated appendicitis. The study is expected to continue until 2027, with recruitment starting in 2025.

The medication being tested, caspofungin (brand name Cancidas), is available in two different strengths: 50 mg and 70 mg. It comes as a powder that is mixed with sodium chloride solution to create a liquid that can be given through a vein. The treatment period lasts for up to 8 weeks, during which patients receive daily doses of either caspofungin or placebo.

During the study, doctors will monitor patients for 28 days after starting treatment to see how well the medication works. They will also track patients’ progress for up to 90 days to gather additional information about the treatment’s effectiveness and safety. The study uses a double-blind design, which means neither the patients nor their doctors know who is receiving caspofungin or placebo during the treatment period.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor changes in the health of several organs, including the lungs, heart, kidneys, liver, and blood, over a period of seven days after the infection source has been controlled. The goal is to see if Pentaglobin can help reduce the severity of multiple organ failure, a condition where several organs stop working properly, which can occur in severe cases of peritonitis and sepsis.

The study will also track other important outcomes, such as survival rates within 28 and 90 days, and changes in the severity of organ failure by the fifth day of treatment. By understanding these effects, researchers hope to determine the potential benefits of using Pentaglobin in treating these serious conditions. The study is designed to provide valuable insights into personalized medicine approaches for patients with peritonitis and sepsis.

The purpose of the study is to compare the impact of starting supplementary parenteral nutrition early versus postponing it on the risk of infections that patients might acquire in the hospital after their surgery. Participants in the study will receive either the early or postponed nutrition treatment, or a placebo, and their progress will be monitored over time. The study aims to see if the timing of the nutrition affects the rate of infections and other complications during the hospital stay.

Throughout the study, researchers will observe various outcomes, such as the rate of complications, the length of hospital stay, and mortality rates at 30, 90, and 180 days after surgery. They will also track the amount and type of energy and protein intake during the hospital stay. This information will help determine the best approach to providing nutrition to patients recovering from major emergency abdominal surgery.